GlassScriptPhysician profile
Min W Kang
NPI 1134197155
$4,075.06
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,279 · 2020: $1,536 · 2021: $1,111 · 2022: $43.62 · 2023: $90.17 · 2024: $15.18.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $105.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $581.70 | 2019-2021 | |
| Pfizer INC. | $491.34 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $407.80 | 2019-2023 | Farxiga, Airsupra |
| Amgen INC. | $307.29 | 2019-2023 | Otezla, Repatha |
| Abbvie INC. | $256.23 | 2021-2024 | |
| Novo Nordisk INC | $254.25 | 2019-2021 | |
| Amarin Pharma, INC. | $212.53 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $198.43 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $183.70 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $172.21 | 2019-2021 | |
| Lilly USA, LLC | $140.83 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $135.21 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $101.69 | 2019-2021 | |
| Insmed, INC. | $63.73 | 2019-2021 | |
| Allergan, INC. | $52.96 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $47.25 | 2020-2021 | |
| Genentech USA, INC. | $42.61 | 2019 | |
| Grifols USA, LLC | $42.21 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $41.31 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.00 | 2020-2021 | |
| Ibsa Pharma INC. | $37.92 | 2019 | |
| Ironshore Pharmaceuticals INC. | $35.11 | 2019 | |
| Supernus Pharmaceuticals, INC. | $31.14 | 2022 | |
| Adlon Therapeutics L.P. | $30.17 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $25.46 | 2021 | |
| Esperion Therapeutics, INC. | $19.95 | 2021 | |
| Ironwood Pharmaceuticals, INC | $18.39 | 2021 | |
| Zyla Life Sciences, INC. | $17.62 | 2019 | |
| Corcept Therapeutics | $16.72 | 2019 | |
| Sunovion Pharmaceuticals INC. | $16.28 | 2020 | |
| Mannkind Corporation | $15.85 | 2019 | |
| Shire North American Group INC | $13.93 | 2019 | |
| Radius Health, INC. | $13.36 | 2019 | |
| Medtronic USA, INC. | $11.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Min Kang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.